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Chapter 10 
Migratory Nonparenchymal Cells Mter 
Organ Allotransplantation: With Particular 
Reference to Chimerism and the Liver 
By THOMAS E. STARZL, ANTHONY J. DEMETRIS, ABDUL S. RAO, 
ANGUS W. THOMSON, MASSIMO TRUCCO, and NORIKO MURASE 
We have proposed recentlyl-7 that the exchange of migratory leukocytes between 
the transplant and the recipient, with consequent long-term chimerism (co-
existence of donor and recipient cells) in both, is the basis for acceptance of whole 
organ allografts and xenografts (Fig 10-1). Although such chimerism was first 
shown only in the spring of 1992, the observations have increased our insight into 
transplantation immunology and have encouraged the development of alternative 
therapeutic strategies. 
LOCAL (GRAFf) CHIMERISM OF THE LIVER 
AND OTHER ORGANS 
It was shown with karyotyping techniques in 1969 that human liver allografts 
become genetic composites (local chimerism). In female recipients of livers 
obtained from male cadaveric donors, the hepatocytes as well as the endothelium 
of the major blood vessels of the grafts retained their donor sex, whereas within 
100 days the entire macrophage system including the KupfIer cells was replaced 
with cells identified as female by their characteristic Barr bodies.s. 9 For more than 
two decades, the composite genetic structure of the hepatic allograft was assumed 
to be a unique feature of this organ. 
This illusion was dispelled in 1991 with the finding, first in rat intestinal 
allograftslO and then in transplanted human bowel,l1 that the epithelium and 
vascular endothelium remained donor, whereas lymphoid, dendritic, and other 
leukocytes were replaced by recipient cells in the lamina propria, Peyer's patches, 
and mesenteric nodes. The same kind of transformation is now known to occur 
with all whole organ grafts.4• 12-16 
DISCOVERY OF SYSTEMIC CHIMERISM 
Indirect Evidence 
Early circumstantial evidence that these cells (the donor leukocytes leaving the 
grafts) were still viable was largely ignored or misinterpreted. For example, it was 
shown in 1963 that delayed hypersensitivity reactions (tuberculin, histoplasmin, 
etc) present in kidney donors were transferred to previously negative recipients 
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Figure 10-1. The mutual engagement of migratory immunocytes from the graft and the recipient 
after organ transplantation under potent pharmacological immunosuppression. GVH, graft-versus-
host; HVG, host-versus-graft. (Reprinted with permission.94) 
with successful renal transplantation,17 but not if the kidney was lost to rejection. 
The explanation that this represented "adoptive transfer of donor cellular 
immunity by leukocytes in the renal graft vasculature and hilar lymphoid tissue"17 
was considered implausible at the time because the kidney was construed to be a 
"leukocyte-poor" organ. 
Clues were also overlooked in liver recipients. In these patients, new donor-
specific immunoglobulin (IgG) types appeared and persisted in the blood. 9,18 
Much later, donor-specific leukocytes were postulated to be the source of anti-red 
blood cell antibodies that developed in recipients of livers from donors who had 
ABO nonidentity.19 Finally, Davies et aFo reported the appearance of donor-
specific soluble class I antigens in the blood of liver recipients that were thought to 
be synthesized by the graft hepatocytes. Because these molecules can also be 
produced by bone marrow-derived macrophages and/or dendritic cells,21-23 a 
more plausible explanation is that they originated from donor chimeric cells in the 
same way as the additional IgG types and anti-red blood cell antibodies. 
Direct Evidence of Chimerism 
During the period of April through June 1992, we began a systematic search for 
ectopic donor leukocytes in rats24- 26 and in human recipients of kidneys, livers, and 
other organs whose successful transplants had been performed many months or 
years earlier. The search in patients was made feasible by the distinctive features 
of two chromosomes: Y chromosomes in females who had been given organs from 
male donors, and/or HLA alleles of chromosome 6 in all patients. In either 
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instance, one or the other of two technologies, and usually both, were exploited. 1- 6 
One was cytostaining, which allows the location and morphological characteriza-
tion of phenotypically distinct donor and recipient cells. The cytostaining for the 
Y probe was with a fluorescence method after in situ hybridization. The 
immunostaining for the HLA markers was with indirect immunofluorescence 
and/or an avidin-biotin-complex immunoperoxidase method, using monoclonal 
antibodies to MHC class I and class II antigen specific for the donor but not the 
recipient. 
The other technology was polymerase chain reaction (PCR), which permits the 
distinction of donor from recipient DNA.1-6 In the PCR search for the Y 
chromosome, oligonucleotides specific for the satellite region of the Y chromo-
some centromere Y-A and for the sex-determining region of the Y chromosome 
were used as primers to determine the presence of male DNA in the female 
recipient tissues. The PCR tests for donor- and recipient-specific HLA alleles of 
chromosome 6 were performed by preliminary generic amplification of the DRB 
gene (encoding the bcta chain of DR), followed by allele-specific amplification 
and testing. 
The Human Kidney Recipients 
Some of these patients, including the longest surviving kidney recipients in the 
world,27 had participated in the skin test studies nearly three decades before 
(discussed previously). Of the five patients studied, one had stopped immunosup-
pression 12 years earlier, whereas thc othcrs were still taking azathioprine with or 
without prednisone. All five had received HLA-incompatible kidneys, which in 
two cases had come from donors of the opposite sex. 
Low-level chimerism was found in the skin, lymph nodes, and often the blood of 
each of these kidney recipients. In addition, biopsies of the allografts showed that 
the cells departing the transplants had been largely replaced by similar cells from 
the host. Thus, both the recipients and their grafts were composed of cells with 
two different genomes.4, 12 
The Human Liver Recipients 
A much larger cohort of 25 liver recipients was studied 2 to 22 years after 
transplantation under azathioprine- or cyclosporine-based immunosuppres-
sion.2,6 Most were clinically well and fully immunocompetent by conventional in 
vitro testing. Donor cell chimerism was found with immunocytochemical or PCR 
techniques in all 25 in locations that included skin, lymph nodes, heart, lungs, 
spleen, intestine, kidneys, bone marrow, and thymus. Chimeric cells were in larger 
numbers at any given site than in the contemporaneously studied long-surviving 
kidney recipients, although the absolute numbers were still quite small. 
CELL TRAFFIC AND SITES OF DONOR-RECIPIENT 
IMMUNOLOGIC INTERACTIONS 
The early events leading to the chimeric state after liver transplantation have 
subsequently been studied in rats7 and mice,28 and the pathways of passenger 
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leukocyte dissemination have been well worked out. Within minutes or hours, 
these cells leave the liver and home to the spleen, lymph nodes, thymus, and bone 
marrow where they are destroyed by rejection in most untreated animals except 
mice or pigs, and some rat strains. However, under temporary immunosuppres-
sion in rats (2 weeks daily FK506 therapy), the donor mononuclear cells pause for 
about 2 weeks in the lymphoid organs, but then move on to all recipient tissues.? 
Presumably similar pathways of dissemination are also taken by donor bone 
marrow-derived cells after whole organ transplantation in humans (Fig 10-2). In 
several rat strain combinations (for example, Brown Norway [BN] to Lewis 
[LEW)), recipients treated in this manner survive indefinitely without further 
treatment and retain their graft and systemic chimerism. 
The permanent survival of engrafted livers without any immunosuppression in 
some rat strain combinations (of which BN ~ LEW has been most completely 
studied29), and in most mouse strains has been poorly correlated with histocompat-
ibility.3D These "nonrejecting" liver recipients in either species and those whose 
liver acceptance is induced with immunosuppression can receive normally 
rejected skin, kidney, or heart from the original donor strain but from no other 
(thus, donor-specific nonreactivity). 
Figure 10-2. The dissemination of bone marrow-derived cells from the graft to the central 
lymphoid organs (left) and then after a brief pause ubiquitously to other recipient's tissues (right). The 
events are similar to those after successful bone marrow transplantation. 
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Hepatic Tolerogenicity 
Although we believe that cell migration and repopulation is the central 
mechanism of acceptance of all whole organ grafts,I-7 there are quantitative and 
qualitative differences between organs in the density of the potentially migratory 
dendritic cells, macrophages, and lymphoid population. The heavy endowment of 
the liver with cells of multiline age phenotypes (especially Kupffer cells) is a 
particularly striking feature that invites further speculation about the role of these 
cells in the well-known tolerogenicity of this organ. Here, tolerance is defined as 
the specific absence of an immune response to an antigen. This is usually an active 
process that is related either to deletion or anergy of antigen-reactive lympho-
cytes, or to a suppressor mechanism. The immunologic advantage of the liver 
relative to other organs includes a greater ease of inducing the acceptance of 
hepatic allografts or xenografts after a limited course of immunosuppres-
sion28,29,31.32 or in some swine33-35 or rat36,37 and virtually all mouse30 strain com-
binations with no treatment at all. 
In addition, the transplanted liver is relatively resistant to the performed 
alloantigraft antibodies that cause hyperacute rejection of the kidney and 
heart.38-41 Another quality is its unusual ability to induce a state of immunologic 
unresponsiveness to other tissues and organs transplanted concomitantly or 
subsequently from the donor or donor strain36, 39, 42 and even shield these organs 
from the hyperacute rejection caused by performed allospecific (against antigens 
from another member of the same species )41 or xenospecific (against antigens 
from different species )43 anti donor antibodies, In all of these circumstances, the 
liver can quickly transform the recipient environment to one more favorable for all 
donor tissues including itself. All of these qualities of the liver are subject to 
analysis in the mouse.30 
The foregoing observations have been attributed to "hepatic tolerogenicity," 
incorrectly we believe, because the term implies that the hepatocytes are 
responsible. We have proposed that the crucial variable distinguishing the 
tolerogenicity of one organ graft from another is its leukocyte, not its parenchymal 
component. 1-7, 30 This is a reversal of the immunogenic role described classically 
for the bone marrow-derived ceIls.44-57 Thus, because of its dense constituency of 
these migratory leukocytes, the liver is high on the favorable tolerogenic list, with 
the lung and intestine a considerable distance behind, and the kidney and heart 
bringing up the rear. Experimental studies showing less striking tolerogenicity of 
the lymphoreticular-rich spleen,58-60 intestine,IO and lung61 , 62 are compatible with 
this generalization. 
Tolerogenicity of Leukocyte-Poor Organs 
The same kind of traffic but in the context of alloactivation (T-cell activation in 
response to alloantigen stimulation) and rejection rather than tolerization was 
well worked out earlier with the so-called lymphoid-poor organs such as the 
kidney, exemplified by the classical study in 1981 by Nemlander et al of untreated 
rat kidney recipients.63 If Nemlander et al had administered one or two doses of 
cyclosporine in his experiments (which were with an "easy" strain combination) 
and had followed up his animals further, we believe that he would have uncovered 
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the events of cell migration and long-term chimerism that awaited another dozen 
years for exposure with the liver. 
Such studies in untreated animals have shown that the alloreaction (the mutual 
interaction of host and donor immune cells) starts in two general sites, peripher-
ally in the graft and centrally in the recipient lymphoid tissues, as was emphasized 
by Nemlander et a1. Larsen et al64 found that donor dendritic cells from 
heterotopic cardiac allografts were released into the circulation, where they 
eventually homed into the T-cell areas of the recipient spleen. In the spleen, the 
donor cells initiate proliferation of recipient cells, and vice versa.63- 67 This 
reaction might be thought of as an in vivo mixed lymphocyte response (MLR) 
(proliferation of alloreactive T cells in response to allogeneic accessory cells) in 
the course of central allosensitization. Failure to appreciate that there was a 
potential alternative outcome of tolerization was the missing link in understand-
ing why whole organ allografts could be accepted. 
Allosensitization (or tolerization) also occurs within the graft. Forbes et a166 
showed that clustering of recipient lymphocytes occurs around donor dendritic 
cells in the interstitium of cardiac grafts, within a few days after transplantation. 
The recipient lymphoid cells undergo blastogenesis and proliferate within these 
clusters. We have described analogous events in rejecting rat livers.6s In human 
recipients of kidney grafts68, 69 receiving cyclosporine-prednisone immunosuppres-
sion, Hayry and Willebrand noted what seemed to be a bidirectional MLR in 
needle aspiration biopsies. When studied with the Staphylococcus aureus assay 
and alloantibodies to nonshared donor and recipient allelic specificities, the 
majority of the isolated blast cells in some of their human cases were derived from 
the donor, whereas in others the cells were both of donor and recipient type, 
"resembling a bidirectional mixed lymphocyte reaction in vitro. "68 
With the various extrahepatic organs, the central or peripheral events seem to 
be only quantitatively different from those following transplantation of the more 
tolerogenic liver. With the smaller number of passenger leukocytes, and perhaps a 
lower representation of subpopulations of certain lineages, there is a greater 
tendency to allosensitization and less to tolerogenicity. Nevertheless, Corry et apo 
and Russell et aFl showed that tolerance without drug therapy could be induced 
by heart and kidney transplantation in mice between weakly MHC-incompatible 
strains, reflected later by permanent acceptance of donor strain skin grafts (but 
not third party). 
FUNCTIONAL CONSEQUENCES OF MICRO CHIMERISM 
Questions as to whether low-level chimerism in long-surviving patients and 
experimental animals is an irrelevant histopathologic curiosity seem naive in view 
of Russell's elegant formal proof of the association of chimerism with acquired 
tolerance as well as with runt disease (graft-versus-host disease [GVHD]).72 
However, the low numbers (microchimerism) of the chimeric donor cells in the 
recipient tissues requires explanation. The term micro chimerism was introduced 
into the literature in 1974 by Liegeois et aF3 to describe a small proportion of 
chimeric cells in the recipient spleen of mice as long as 5 months after bone 
marrow transplantation. The cumulative effect of these microchimeric cells is 
substantial, especially after liver transplantation when they are most easily shown. 
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How Do Donor Cells Perpetuate? 
A key question concerns how the chimeric cells survive and perpetuate within 
tissues of organ allograft recipients long after transplantation. In recent labora-
tory experiments, we have examined whether progeny of the chimeric cells present 
within various tissues of unmodified liver allograft recipients can be generated in 
vitro under appropriate culture conditions,14-76 In freshly prepared cell suspen-
sions from recipient's bone marrow, spleen, or thymus l4 or 150 days posttrans-
plant, only very low levels of chimeric cells (donor MHC class 1+) can be shown. 
However, following stimulation of the cells with granulocyte-macrophage colony-
stimulating factor for 10 days we have succeeded in propagating not only recipient 
cells but also large numbers of myeloid cells bearing donor phenotype (MHC class 
F or class IF). These observations suggest that progenitors have migrated from 
the allograft and seeded into different host tissues, and provide an explanation for 
the perpetuation of stable donor cell chimerism for decades after human organ 
transplantation. 
Metabolic Effects 
A small population of chimeric cells has been shown to affect total body 
metabolism in patients treated with liver transplantation for the enzyme deficien-
cies of type IV glycogen storage disease and Gaucher's disease. These disorders in 
which the consequences of the missing enzymes are widespread storage of 
amylopectin and glucocerebroside, respectively,3 were previously thought to be 
treatable only by bone marrow transplantation. Yet, 2 to 8 years after liver 
replacement, there was a dramatic resorption of both kinds of storage material 
from host tissues3 for type IV glycogen storage disease. As an explanation for the 
metabolic amelioration, chimeric donor cells were found ubiquitously in recipient 
tissues including heart, lymph nodes, bone marrow, intestine, and skin. There 
apparently had been a co-culture effect of a small number of enzyme-replete 
chimeric donor cells on the contiguous overwhelming numbers of enzyme-
deficient recipient cells leading to resolution of abnormal amylopectin deposits. 
The Immunologic Interface 
The potential effect of cell-to-cell interaction and its role in immunologic rather 
than metabolic processes cannot be so easily measured. In an earlier section (How 
Do Donor Cells Perpetuate), the demonstration of dendritic cell precursors was 
described in mouse livers, blood, and bone marrow,?4-76 Under most circum-
stances, the progeny of these precursor cells would be expected to reach terminal 
differentiation unless there is a need for their continued proliferation, or else 
maintenance of a pool of precursor population. We have suggested that the 
survival and continued renewal of these cells depends on chronic mutual 
stimulation of the donor and recipient cells,S, 7 highlighting not only the common-
ality between the cellular processes involved in tolerization and immunity,77 but 
the changes that occur in these cells. 
Changed Host and Graft Interactions 
There are indirect ways to show that the coexisting immunocyte populations in 
successful cases (Fig 10-1) come to regard each other in a revised light. The 
evidence on one hand is the fading of the threat of clinical rejection concomitant 
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with development of donor-specific nonreactivity in spite of lightened treatment 
(or in some animal models with no treatment at all) and on the other, the waning 
specter of GVHD. In a human organ recipient, both cell populations are subject 
to the treatment conditions because both have the same protective umbrella of 
immunosuppression during the process of change. 
The appreciation of the interactions between the donor and recipient cells and 
the overwhelming need to preserve this relationship by refraining from cytoablat-
ing one side or the other was the crucial advance that permitted the successful 
engraftment of leukocyte-rich organs such as the liver or intestine, both together, 
or all of the intraabdominal organs (multivisceral transplantation).78 Once the 
cardinal principle was understood that low-level mixed allogeneic chimerism 
invariably was found after the successful transplantation of any whole organ, the 
reason seemed obvious why GVHD was not common in liver, intestinal, or 
multivisceral recipients. Mixed chimerism was being produced in the same way as 
had been documented in the classical GVHD free mouse bone marrow mixed 
chimerism models of Slavin et aF9 and Ildstad and Sachs,80 although the number 
of donor cells was much lower. 
The Critical Dendritic Cell 
Generation of an immune response leading under normal circumstances to 
graft destruction and/or GVHD requires effective antigen presentation and 
recognition in its initial phase followed by a second costimulatory signal and the 
response of the naive T cells to the combined signal.81 Both of these signals are 
normally delivered to T cells by professional antigen presenting cells (APCs). 
Although any cell that expresses an appropriate MHC class II molecule can 
present antigen to sensitized T cells, it is only dendritic cells that are thought to be 
most efficient in presenting antigens to naive T cells.46-48 Dendritic cells, which are 
of bone marrow origin (CD45+), are ubiquitously distributed throughout the 
body. They have an irregular shape, small round phase-dense mitochondria and 
sparse, rough endoplasmic reticulum. They are nonphagocytic in culture, and 
express very low levels of Fc and complement receptors. However, they constitu-
tively express high levels of MHC class I and II antigens and can upregulate 
B7/BBl molecule. Because the cell surface expression of these molecules can be 
modified, they playa major role in determining how antigen signals are heeded by 
T cells.49 Furthermore, by morphological criteria, the most abundant chimeric 
cells in whole organ transplant recipients were dendritic cells.l-7 Thus, the 
dendritic leukocyte is the prime candidate for mediator of tolerance induction 
even though other lineages (eg, B or even T cells) may also be essential for a 
successful outcome. 
The "Blindfolding" of Tissue Matching 
In both the directions of host-versus-graft (HVG, rejection) and GVH, cellular 
interactions resulting in "mutual natural immunosuppression" are envisioned as 
occurring on a sliding scale with each further level of histoincompatibility. With 
effective immunosuppression, it has been increasingly possible to orchestrate the 
outcome of donor and recipient cell cngagement after transplantation in a 
manner that would allow the tolerogenic changes to occur and a compromise to be 
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reached between the coexisting immunocytes. The anticipated influence of 
his to incompatibility on both rejection and the severity of GVHD are then 
expected to dwindle. We have postulated l ,4-6 that this explains the poor 
correlation of HLA matching with outcome after the cadaveric transplantation of 
whole organs including the kidney.82-84 With liver transplantation, two large 
centers actually have reported an inverse relation between HLA matching and the 
clinical outcome.85,86 Furthermore, it has been proposed that HLA-DR matching 
increases the risk of cytomegalovirus (CMV) hepatitis in both primary and 
secondary CMV infections.87 
RELATION OF CELL MIGRATION TO TOLERANCE 
The inadequacy of thymic clonal deletion to explain acquired transplantation 
tolerance has been emphasized in recent reviews.88 Although a discussion ofthe 
meaning of tolerance is beyond our intention, it should be noted that all of the 
mechanisms put forth to explain clonal "silencing" including peripheral (nonthy-
mic) clonal deletion and anergy could mesh with the discovery of the enduring 
graft-host intimacy that is inherent with chimerism. The production of suppressor 
and/or veto cells (cells capable of inactivating or suppressing the activity of 
cytotoxic T lymphocytes) could be epiphenomenologic consequences. The evi-
dence of long-term vitality and turnover of donor leukocytes in recipient tissues is 
particularly supportive of the opinions of Bandeira et al,77 Coutinho89 and Cohen90 
who have defined acquired tolerance as a high (not anergic) level of sustained 
immune activity in immunologic networks. These networks presumably interact in 
a more complex way than the idiotype systems originally postulated by Jerne.91 
Apart from explaining why the events of convalescence follow the same pattern 
of vigorous immune resistance and then collapse after all transplantations, no 
matter what the organ,28, 31, 92 the cell migration-chimerism concept also shows 
how donor-specific nonreactivity can be achieved with a common mechanism, 
irrespective of the site of action of the immunosuppressive drugs or, in some 
experimental models, without the need for drugs. It has been proposed from 
observations in drug-free models of tolerance induction that occupancy of T-cell 
receptor (TCR) leads to production of negative regulators of interleukin-2 (IL-2) 
production (anergy proteins).81, 93 According to this hypothesis, during the course 
of a normal T-cell response (to alloantigens) these negative regulators of IL-2 
production have an inconsequential effect because they are diluted out by 
vigorous cell replication driven by IL-2. However, these negative regulators would 
accumulate with consequent anergy if clonal expansion were prevented at any 
level (Fig 10-3): for instance, by the absence of a co-stimulatory signal in drug-free 
models.81 
The same effect could be induced iatrogenically by pharmacological interdic-
tion of IL-2 gene transcription (cyclosporine and FK506) or administration of a 
DNA synthesis inhibitor (azathioprine, cyclophosphamide, and numerous oth-
ers). The use of non-T-cell-depleting monoclonal antibodies, such as those 
directed against the cell surface CD4 antigen or monoclonal antibodies against 
adhesion molecules including intracellular adhesion molecule-1 and lymphocyte 
function-associated antigen-194 can also be envisaged. 
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Figure 10-3. Model of dendritic cell (APC)-Thrcell interaction, showing the production within the 
nucleus of positive (+) and of negative (-) regulators (putative anergy proteins) of IL-2 gene 
transcription. It has been suggestedH1 that TcR occupancy leads to the production, through an active 
metabolic process, of negative regulators (anergy proteins) that accumulate at later times and repress 
IL-2 gene transcription, possibly by antagonizing the efIects of positive gene transcription factors. In 
the absence of persistent costimulatory signals (or under the umbrella of immunosuppressive drugs), 
cell division does not proceed and negative nuclear regulators accumulate, resulting in T-cell anergy. 
In addition to the action of immunosuppressive agents, chronic antigen stimulation is also envisaged as 
promoting anergy. In some instances, tolerance can be broken, eg, by administration of exogenous 
IL-2. HVG, host-versus-graft response (allograft rejection); GVHD, graft-versus-host disease. 
(Reprinted with permissionY4) 
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Whatever the mechanism, the reciprocal educational process of donor and 
recipient leukocytes and its perpetuation resembles in either the direction of 
HVG or GVHD (Fig 10-3) the "infectious" transplantation tolerance of 
Waldmann and Cobbold that can be passed on to naive lymphocytes and be 
self-sustaining in some circumstances.95 It is postulated that in fully successful 
cases, the mini-immune system of the graft is incorporated into the existing 
recipient immunologic network,S. 7 compatible with the hypothesis of Coutinho.89 
UNSTABLE MIXED CHIMERISM 
Cell migration conceptually reunites bone marrow transplantation with trans-
plantation of whole organs. Far from involving different mechanisms for success-
ful engraftment, we believe that these two seemingly disparate clinical disciplines 
merely reflect contrasting treatment dogmas. For bone marrow transplantation, 
the conventional treatment strategy of recipient cytoablation eliminates mutual 
immunocyte engagement and thus necessitates heavy reliance on HLA matching 
to prevent GVHD in the unbalanced system. The treatment for solid organ 
transplantation encourages, or at least allows, these consequences of mutual cell 
engagement, thereby liberating the patient from the restrictions of HLA matching 
and an overwhelming threat of GVHD. 
Failure of the chimeric donor and recipient immunocytes to reach an immuno-
logic "truce" (Fig 10-1) leads to rejection of the transplanted whole organ on one 
hand and to GVHD on the other, or sometimes to both simultaneously. This has 
been particularly well studied after intestinal transplantation between certain rat 
strain combinations involving the Brown Norway (BN) strain.24-26 In ACI, PVG, 
or LEW rats treated daily with variable doses of FK506 for the first 14 days after 
transplantation and weekly thereafter, successful intestinal transplantation from 
fully allogeneic BN donors was not complicated by either rejection or by fatal 
GVHD.26 In contrast, when BN was the recipient, rejection of the ACI intestine 
was difficult to control, and when LEW or PVG intestine was transplanted, 
GYHD invariably developed once the daily treatment was stopped. Yet, the 
two-way lymphocyte traffic from graft to host lymphoid organs and vice versa was 
similar with either strain direction.24,25 Saat et al97 have described analogous 
findings of GVHD predisposition and rejection under cyclosporine after WAG to 
BN rat intestinal transplantation but not BN to WAG. 
Further experiments in our laboratory have not clarified why the BN rat is an 
"easy" donor and a "difficult" recipient. At a clinical level, the unresolved 
practical question is how to identify and avoid bad donor-recipient combinations 
analogous to LEW, ACI, or PVG to BN rats, particularly when immunologically 
active organs such as the liver and intestine are engrafted. 
With human liver transplantation, preoccupation with rejection long obscured 
the fact that the graft-versus-host reaction, which is an incipient process and in 
our opinion a requisite for sustained engraftment in every case, can evolve to 
serious or fatal syndromes98-105 in the early postoperative period. Clinically 
recognizable GVHD is observed in our liver program in approximately 5% to 10% 
of cases, usually manifesting as trivial dermatitis.6 In the past, this usually was 
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Figure 10-4. Fluorescent in situ hybridization for X [red) and Y [yellow) chromosomes in 
cytocentrifuge preparations of peripheral blood cells obtained from (A) normal male [positive control J 
and (B) a female recipient of male kidney and bone marrow 235 days after transplantation. 
Biotinylated Y-specific and digoxigenin-conjugated X-specific probes were used, which were visualized 
with fluorescein isothiocyanate-conjugated avidin and tetramethylrhodamine isothiocyanate-
conjugated antidigoxigenin, respectively. Nuclei were counterstained with 4,6-diamino-2-phenylin-
done. 
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attributed to a self-limiting drug reaction or an allergic manifestation, but with 
techniques of donor cell identification, the true diagnosis can be readily made. 
Although most of these patients can be treated successfully with increased 
immunosuppression (particularly prednisone) or occasionally by decreasing 
treatment, liver recipients with extensive skin involvement, gastrointestinal 
symptoms, and depression of the formed blood elements have a high mortality.l03 
The chimerism that has been documented in such patients has differed only by 
being more extensive than that observed in patients who have a benign 
convalescence. 
CLINICAL TRIALS OF BONE MARROW AUGMENTATION 
Summary of Experience 
The overview developed in this chapter is that the migration from organ 
allografts of donor leukocytes and their ubiquitous persistence in recipient tissues 
is the seminal explanation for allograft acceptance, and the first stage in the 
development of donor specific nonreactivity (tolerance). In a direct extension of 
this concept, 16 unconditioned patients were infused with donor bone marrow 
cells on the day of cadaveric renal (n = 9), liver (n = 6), and heart (n = 1) 
transplantation. The 16 patients, who were also treated with standard FK506-
prednisone immunosuppression, included three diabetics who also received 
pancreatic islets and a liver recipient with a positive lymphocytotoxic crossmatch. 
All 16 patients have good whole organ function 3.5 to 14 months later (mean 
serum bilirubin of liver recipients, 0.6 mg/dL; mean serum creatinine of kidney 
recipients, 1.5 to 1.7 mg/dL; good cardiac function in heart recipient); two ofthe 
three diabetics have detectable C-peptide activity. Using flow cytometry and 
qualitative or quantitative PCR techniques to detect donor HLA alleles and with 
study of Y chromosomes in four female recipients of male organs, persistent 
multiline age leukocyte chimerism was found in the blood of all recipients by 
Southern analysis of the Y chromosome-specific SRY gene (not shown), and as 
otherwise shown in Fig 10-4 and Table 10-1, except one patient whose complete 
HLA match and same-sex donor precluded study (Table 10-1). Rejection in 9 
(56%) of the 16 patients and transient GYHO in 2 (12.5%) was diagnosed and 
successfully treated (Table 10-1). Sustained donor specific hyporeactivity as early 
as 40 or 50 days postoperatively was demonstrable with in vitro tests in the majority 
of recipients (Table 10-1). 
The Old Paradigm and Its Fit With The New One 
Tolerance induction with donor leukocytes is the most ancient therapeutic 
strategy of transplantation. It was introduced with the injection of spleen cells in 
fetal or perinatal mice by Billingham et al,106 and extended by Main and Prehn to 
the production of radiation chimeras with bone marrow cells. 107 Hundreds of 
subsequent tolerance induction experiments and eventually clinical bone marrow 
transplantation depended on a similar natural or imposed defenseless recipient 
state. The first exception, reported by Mariani et aP08 was induction of tolerance 
with splenocytes to the sex-linked (Eichwald-Silmser) histocompatibility differ-
------------~-~---------------------------
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Table 10-1. In Vitro lmmune Status and the Detection of Donor Cells in the Combined Bone Marrow 
and Whole Organ Recipients 
Detection of Donor Cells 
HVG' GYHt MLR Rcsponse:j: FACS PCR 
Case No. Allografts (POD) (POD) % (POD) POD§ (%) (cPCR) 
Liver + islets 15,86 None 34 (85) 82 1.7 + 
2 Liver 7,22 None 36 (108) 108 1.8 + 
3 Liver None 54 6 (120) 14611 1.9 + (1.0%) 
4 Liver None 21,74 87 (145) 167 <0.5 + 
5 Liver 33 None Low responderll 175 5.0 + 
6 Liver 24 None 15 (265) 265 NF# + 
7 Kidney None None 59 (48) 48 1.7 + 
8 Kidney None None 5 (72)" 19 NF# NFtt 
9 Kidney None None 70 (113) 120 1.9 + 
10 Kidney + islets 41,66 None 5 (166) 133 1.4 + 
11 Kidney + islets 16 None 50 (168) 171 3.0 + 
12 Kidney None None 22 (225) 225 0.6 NFtT 
13 Kidney 16 None 18 (177) 232 NF# + 
14 Kidney 16 None 26 (68)** 315 <0.5 + 
15 Kidney None None NF:j::j: 367 NF# + (0.5%) 
16 Heart 12-40§§ None 130 (65) 68 1.5 + 
* Host -versus-graft reaction [rejection]. 
tOraH -versus-host reaction. 
:j:Percentage of donor-specific MLR responses as compared to third party on the last sample tested. 
§Last postoperative day (POD) tested. 
liThe samples for PCR and cPCR were obtained on POD 128. 
If Cells did not respond to any stimulation in vitro for up to POD 134. 
#Not feasible; cross-reactive antibodies_ 
"No change in donor-specific responses before and after transplant. 
ttNot feasible; no MHC class II mismatch. 
**Not feasible; no adequate donor spleen cells. 
§§Single rejection episode, gradually resolving from grade 3A (multi focal moderate acute cellular rejection 
[ACR]) on POD 12 to grade 113 (diffuse mild ACR) on POD 40. All subsequent biopsies were negative. 
ence in unconditioned adult syngeneic mice, and then in a limited number of 
allogeneic mouse strains by Brent and Gowland109 and other investigators. 
The discovery by Billingham and Brent 110 and Trentin111 that GVHD was the 
penalty for preexisting or iatrogenic general immunologic nonreactivity fore-
stalled for many years the clinical use of major histocompatibility complex 
(MHC)-mismatched bone marrow or other mature immunocytes to facilitate 
whole organ graft acceptance. 1I2• 113 The alternative of using killed donor cells was 
relatively ineffective as first reported in a clinical renal transplantation trial by 
Kelly et aP14 in 1967. 
In contrast, donor blood seemed to be tolerogenic if it was transfused fresh as in 
the canine experiments of Halasz et al. 1I5 Explanations for the experimental 
effect, and later the seeming benefit in clinical kidney transplantation of 
donor-specific116 or third-party transfusions,117 were hampered by uncertainty 
about the timing of optimal treatment, the inability to quantitate cell dose, and 
variable policies of conserving (or deliberately eliminating) the leukocyte constitu-
ency of the blood. In addition, few investigators looked for persistent chimerism, 
-_. __ . ----------------------
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perhaps because of the evidence that allogeneic leukocytes had a transient life 
span.IIB However, based on circumstantial evidence, van Twuyver et aPl9 
postulated that the blood transfusion benefit was caused by persistent microchime-
rism, the term that had been introduced to the literature by Liegeois et aF3 in 
1974. 
Bone marrow also has been used as the leukocyte source with the explicit 
objective of establishing long-term chimerism. The concept that engrafted 
allogeneic (and xenogeneic) immune cells carried a low risk of GYHO if they 
coexisted with host cells (mixed chimerism) was based on observations in rat 
recipients conditioned preoperatively with total lymphoid irradiation (TLI) by 
Slavin et aF9 and in mice prepared for the marrow with total body irradiation in a 
sophisticated model developed by Ildstad and Sachs.so Clinical trials of bone 
marrow plus preconditioning with TLI were performed in kidney,120 heart,121 and 
liverl22 recipients. In spite of the expectation of GYHO freedom, one of two 
human liver-bone marrow recipients conditioned with 550-R TLI at the Univer-
sity of Pittsburgh developed severe GYHO and eventually died of multiple 
complications.122 Although TLT is still sporadically used, its use with marrow 
augmentation has fallen into disfavor. 
An alternative strategy that also results in preconditioning of the recipient 
before infusion of adjuvant donor bone marrow has been called the "Monaco 
model" following its orderly development in mouse,123 dog,124 and subhuman 
primate l25 models before application in a human case of cadaver renal transplan-
tation in 1973,126 In 1987-1989, Barber et apn used a similar regimen but with 
more effective drugs in 57 patients whose cadaver kidney transplants were 
required to be functioning at the end of 21 postoperative days for entry into the 
trial. 
Immunosuppression during the provisional 3 weeks was with polyclonal 
antilymphocyte globulin and prednisone to which azathioprine and cyclosporine 
were added by day 6. Graft survival in the test series was significantly better than 
in contemporaneous controls, and there was other clinical evidence of benefit 
including a reduced need for immunosuppression. Chimerism in blood samples 
was detected by PCR long after transplantation in an unstipulated number of 
recipients,127 an observation confounded by a significant incidence as well in the 
nonmarrow controls (A.G. Diethelm and W.H. Barber, personal communication, 
January 1993). 
The latter unexpected finding subsequently explained the observation that is 
the central theme of this review-the detection of low-level leukocyte chimerism 
in the tissues of all long-surviving organ recipients and in the blood of many, most 
obviously in liver transplant recipients. I, 2, 4, 6 We have postulated that the multiple 
immunobiological changes seen in organ recipients (eg, altered cytokine profiles, 
suppressor and veto cells, enhancing antibodies) are derived from the sustained 
two-way interactions between the coexisting donor and recipient immunocyte 
populations. I. 5-7, 3D, 75_ 128 
Because the chimeric leukocytes dispersed from the allograft are of bone 
marrow origin, a corollary expectation was that acceptance of organs less 
tolerogenic than the liver such as the heart and kidney (or even the liver itself) 
would be facilitated by augmenting this natural process with the infusion of 
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unaltered donor bone marrow perioperatively.1,4--6 The results thus far are 
consistent with this hypothesis. The ease with which detectable chimerism could 
be reliably produced and sustained without "making space" for the infused bone 
marrow by host cytoreduction and with no deviation from standard immunosup-
pressive management was surprising. All 15 testable recipients of kidneys, livers, 
and a heart have good transplant function and blood chimerism estimated to be 
1,OOO-fold greater than in our earlier studies of naturally occurring chimerism. 
Care was taken not to overestimate the presence or the magnitude of the 
chimerism by the use of corroborating cytological and molecular techniques, blind 
reading of samples, and a new PCR method to quantitate donor DNA. 
Almost invariably, an initial surge of donor cells diminished to a nadir at 
approximately 1 month as well and other investigators have described after organ 
transplantation without marrow.l29,130 However, instead of disappearing, these 
cells secondarily increased to a stable equilibrium level (Figure 10-4) as was 
particularly well documented with a competitive PCR technique. l3l In spite of the 
sustained chimerism, the diagnosis of rejection in nine patients (56%) and minor 
GVHD in two (12.5%) underscores earlier warnings that chimerism is not 
synonymous with tolerance, but only a necessary condition for its achieve-
ment. l, 5, 6,132 The pitfall of extrapolating the association of chimerism and rapid 
tolerance induction commonly seen in rodent experiments to the management of 
human recipients of HLA-mismatched organs could not be more clearly illus-
trated than with the clinical experience herein reported. The pace of drug 
weaning with the eventual goal of drug discontinuation will have to be determined 
in each of our patients individually, with guidance from serial tests of in vitro 
immune reactivity. Although the majority of our 16 patients have evidence of 
evolving donor-specific nonreactivity by in vitro testing, no one has yet had their 
therapy stopped. 
Thus, what we have shown so far is the ability to systematically produce 
persistent and readily detectable chimerism with the expectation that it will confer 
an advantage. Whether the chimerism will evolve to a state no longer requiring 
drugs, and with what frequency, remains to be seen. Beyond its adjuvant role for 
whole organ transplantation, it will be important to determine if MHC-
mismatched bone marrow engrafted under this management regimen can be used 
without an accompanying organ in patients whose disease can be corrected with a 
mixed chimeric state. The potential list of such indications is exhaustive, 133 
exemplified by the lysosomal enzyme deficiencies.3 In addition, the new insight 
obtained about appropriate timing should be applicable to donor-specific blood 
transfusion with which the white blood cell effect presumably is comparable to 
that of a small dose of bone marrow. 
Whatever the source of leukocytes, studies of the interactions between the 
coexisting donor and recipient cell populations, the key lineages governing the 
outcome, and the cellular and molecular mechanisms involved may show ways to 
expand the perioperative window of opportunity shown by our observations. 
However, pretransplant cell infusion carries a known risk of sensitization,116 and 
delayed administration of donor immunocytes can cause rejection.124 In addition, 
it was recently shown in rat experiments that the engraftment of bone marrow, 
followed by second-stage transplantation of a liver allograft with its high content 
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of naive donor leukocytes, frequently resulted in GVHD resembling the parent to 
F] hybrid defenseless host syndrome.7 
SUMMARY 
Evidence has been summarized that the migration from organ allografts of 
donor leukocytes of bone marrow origin and their ubiquitous persistence in 
recipient tissues is the previous unrecognized seminal explanation for allograft 
acceptance, and the first stage in the development of donor-specific nonreactivity 
(tolerance). The unusual immunologic privilege of the liver (called hepatic 
tolerogenicity) has been explained by its heavy content of leukocytes and its 
diverse lineage profile that includes precursor dendritic cells. In a direct extension 
of this new and generically applicable paradigm of transplantation immunology, 
unconditioned patients have been infused with donor bone marrow cells on the 
day of cadaveric liver, renal, and heart transplantation and treated otherwise with 
standard FK506-prednisone immunosuppression. All of the first 16 patients on 
this protocol have good whole organ function 2.5 to 13 months later. Using flow 
cytometry and qualitative or quantitative PCR techniques to detect donor HLA 
alleles, and with study of Y chromosomes in female recipients of male organs, 
persistent multilineage leukocyte chimerism was regularly found in the blood of 
these recipients. Rejection was diagnosed and successfully treated in 9 (56%) of 
these first 16 patients and transient GVHD in 2 (12.5%). Sustained donor-specific 
hypo reactivity as early as 40 days postoperatively was demonstrable with in vitro 
tests in the majority of these recipients. 
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